Considerations towards a population health approach to reduce prescription opioid-related harms (with a primary focus on Canada)

Drugs: Education, Prevention and Policy

Volumn 22, Issue 1, 2015, Pages 60-65

  Fischer, Benedikt ^a,b,c   Burnett, Chantal ^a,b   Rehm, Jürgen ^b,c,d  

^a SIMON FRASER UNIVERSITY   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Non medical use; Policy; Population health; Prescription opioids; Prevention

Indexed keywords

EID: 84920983198     PISSN: 09687637     EISSN: 14653370     Source Type: Journal    
DOI: 10.3109/09687637.2014.936827     Document Type: Article

References (67)

1. Babor, T., Caetano, R., Casswell, S., Edwards, G., & Giesbrecht, N. (2010). Alcohol: No ordinary commodity: Research and public policy. London: Oxford University Press.
2. Bachs, L.C., Engeland, A., Mørland, J.G., & Skurtveit, S. (2009). The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. Clinical Pharmacology and Therapeutics, 85, 596-599.
3. Ballantyne, J.C., & Shin, N.S. (2008). Efficacy of opioids for chronic pain: A review of the evidence. The Clinical Journal of Pain, 24, 469-478.
4. Banta-Green, C.J., Maynard, C., Koepsell, T.D., Wells, E.A., & Donovan, D.M. (2009). Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users. Addiction, 104, 775-783.
5. Bloor, R.N., McAuley, R., & Smalldridge, N. (2005). Safe storage of methadone in the home-An audit of the effectiveness of safety information giving. Harm Reduction Journal, 2, 9.
6. Brennan, F., Carr, D.B., & Cousins, M. (2007). Pain management: A fundamental human right. Anesthesia and Analgesia, 105, 205-221.
7. British Columbia Ministry of Health. (2010). Healthy minds, healthy people: A 10-year plan to address mental health and substance use in British Columbia. Vancouver, BC: Ministry of Health Services and Ministry of Children and Family Development.
8. Centers for Disease Control and Prevention (CDC). (2012). Communitybased opioid overdose prevention programs providing naloxone, United States, 2010. MMWR Morbidity and Mortality Weekly Report, 61, 101-105.
9. Chou, R. (2009). 2009 clinical guidelines from the American pain society and the American academy of pain medicine on the use of chronic opioid therapy in chronic noncancer pain: What are the key messages for clinical practice? Polskie Archiwum Medycyny Wewnetrznej, 119, 469-476.
10. Chou, R., Ballantyne, J.C., Fanciullo, G.J., Fine, P.G., & Miaskowski, C. (2009). Research gaps on use of opioids for chronic noncancer pain: Findings from a review of the evidence for an American pain society and American academy of pain medicine clinical practice guideline. The Journal of Pain, 10, 147-159.
11. Dasgupta, N., Kramer, E.D., Zalman, M.A., Carino, S., Smith, M.Y., Haddox, J. D. Wright 4th, C. (2006). Association between nonmedical and prescriptive usage of opioids. Drug & Alcohol Dependence, 82, 135-142.
12. Dhalla, I.A., Mamdani, M.M., Gomes, T., & Juurlink, D.N. (2011). Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. Canadian Family Physician, 57, e92-e96.
13. Dhalla, I.A., Mamdani, M.M., Sivilotti, M.L., Kopp, A., Qureshi, O., & Juurlink, D.N. (2009). Prescribing of opioid analgesics and related mortality before and after the introduction of longacting oxycodone. Canadian Medical Association Journal, 181, 891-896.
14. Edlund, M.J., Martin, B.C., Fan, M.Y., Devries, A., Braden, J.B., & Sullivan, M.D. (2010). Risks for opioid abuse and dependence among recipients of chronic opioid therapy: Results from the TROUP study. Drug and Alcohol Dependence, 112, 90-98.
15. Expert Working Group on Narcotic Addiction. (2012). The way forward: Stewardship for prescription narcotics in Ontario. Ontario: Ontario Ministry of Health and Long-Term Care.
16. Fischer, B., & Argento, E. (2012). Prescription opioid related misuse, harms, diversion and interventions in Canada: A review. Pain Physician, 15, ES191-ES203.
17. Fischer, B., Bibby, M., & Bouchard, M. (2010). The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in North America: A review of sourcing routes and control measures. Addiction, 105, 2062-2070.
18. Fischer, B., Ialomiteanu, A., Boak, A., Adlaf, E., Rehm, J., & Mann, R. (2013). Prevalence and key covariates of non-medical prescription opioid use among the general secondary student and adult populations in Ontario, Canada. Drug and Alcohol Review, 32, 276-287.
19. Fischer, B., Jones, W., & Rehm, J. (2013). High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009. Pharmacoepidemiology and Drug Safety, 22, 438-442.
20. Fischer, B., Keates, A., Bühringer, G., Reimer, J., & Rehm, J. (2014). Prescription opioid misuse: Why so markedly higher in North America compared to the rest of the world? Addiction, 109, 177-181.
21. Fischer, B., Lusted, A., Roerecke, M., Taylor, B., & Rehm, J. (2012). The prevalence of mental health and pain symptoms in general population samples reporting non-medical use of prescription opioids: A systematic review and meta-analysis. Journal of Pain, 13, 1029-1044.
22. Fishbain, D.A., Cole, B., Lewis, J., Rosomoff, H.L., & Rosomoff, R.S. (2008). What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Medicine, 9, 444-459.
23. Franklin, G.M., Mai, J., Turner, J., Sullivan, M., Wickizer, T., & Fulton-Kehoe, D. (2012). Bending the prescription opioid dosing and mortality curves: Impact of the Washington state opioid dosing guideline. American Journal of Industrial Medicine, 55, 325-331.
24. Gomes, T., Juurlink, D.N., Moineddin, R., Gozdyra, P., Dhalla, I., Paterson, M., Mamdani, M. (2011). Geographical variation in opioid prescribing and opioid-related mortality in Ontario. Healthcare Quarterly, 14, 22-24.
25. Gomes, T., Redelmeier, D., Juurlink, D., Dhalla, I., Camacho, X., & Mamdani, M. (2013). Opioid dose and risk of road trauma in Canada A population-based study. JAMA Internal Medicine, 173, 196-201.
26. Government of Canada. (2005). National framework for action to reduce the harms associated with alcohol and other drugs and substances in Canada: Answering the call (first edition). Ottawa, ON: Drug Strategy and Controlled Substances Programme and Canadian Centre on Substance Abuse.
27. Green, T.C., Heimer, R., & Grau, L.E. (2008). Distinguishing signs of opioid overdose and indication for naloxone: An evaluation of six overdose training and naloxone distribution programs in the United States. Addiction, 103, 979-989.
28. Hemenway, D. (2001). The public health approach to motor vehicles, tobacco, and alcohol, with applications to firearms policy. Journal of Public Health Policy, 22, 381-402.
29. Herring, M.E., Shah, S.K., Shah, S.K., & Gupta, A.K. (2008). Current regulations and modest proposals regarding disposal of unused opiods and other controlled substances (special communication). The Journal of the American Osteopathic Association, 108, 338-343.
30. Hojsted, J., & Sjogren, P. (2007). Addiction to opioids in chronic pain patients: A literature review. European Journal of Pain (London, England), 11, 490-518.
31. Jones, C.M., Mack, K.A., & Paulozzi, L.J. (2013). Pharmaceutical overdose deaths, United States, 2010. The Journal of the American Medical Association, 309, 657-659.
32. Katz, N.P., Birnbaum, H.G., & Castor, A. (2010). Volume of prescription opioids used nonmedically in the United States. Journal of Pain & Palliative Care Pharmacotherapy, 24, 141-144.
33. Kim, D., Irwin, K.S., & Khoshnood, K. (2009). Expanded access to naloxone: Options for critical response to the epidemic of opioid overdose mortality. American Journal of Public Health, 99, 402-407.
34. Luger, L., Bathia, N., Alcorn, R., & Power, R. (2000). Involvement of community pharmacists in the care of drug misusers: Pharmacy-based supervision of methadone consumption. International Journal of Drug Policy, 11, 227-234.
35. Lynch, M.E., & Fischer, B. (2011). Prescription opioid abuse: What is the real problem and how do we fix it? Canadian Family Physician, 57, 1241-1242.
36. Madadi, P., Hildebrandt, D., Lauwers, A.E., & Koren, G. (2013). Characteristics of opioid-users whose death was related to opioidtoxicity: A population-based study in Ontario, Canada. PLoS One, 8, e60600.
37. Manchikanti, L., Helm, S., Fellows, B., Janata, J., Pampati, V., Grider, J., & Boswell, M.V. (2012). Opioid epidemic in the United States. Pain Physician, 15, ES9-ES38.
38. Mendelson, J., Flower, K., Pletcher, M., & Galloway, G. (2008). Addiction to prescription opioids: Characteristics of the emerging epidemic and treatment with buprenorphine. Experimental & Clinical Psychopharmacology, 16, 435-441.
39. Modarai, F., Mack, K., Hicks, P., Benoit, S., Park, S., Jones, C., Paulozzi, L. (2013). Relationship of opioid prescription sales and overdoses, North Carolina. Drug and Alcohol Dependence, 132, 81-86.
40. National Advisory Committee on Prescription Drug Misuse. (2013). First do no harm: Responding to Canada's prescription drug crisis. Ottawa, ON: Canadian Centre on Substance Abuse. Retrieved from http://www.ccsa.ca/2013%20CCSA%20Documents/Canada-Strategy-Prescription-Drug-Misuse-Report-en.pdf?utm-source=NR&utm-medium= NewsRelease&utm-campaign=Rx2013.
41. Office of the Chief Coroner of Ontario. (2012). Office of the chief coroner report for 2009-2011.
42. Toronto, ON: Ministry of Community Safety and Correctional Services. Retrieved from http://www.mcscs.jus.gov.on.ca/stellent/groups/public/@mcscs/@www/@com/documents/webasset/ec161620.pdf.
43. Paulozzi, L., Kilbourne, E.M., & Desai, H.A. (2011). Prescription drug monitoring programs and death rates from drug overdose. Pain Medicine, 12, 747-754.
44. Potter, J.S., Marino, E.N., Hillhouse, M.P., Nielsen, S., Wiest, K., Canamar, C.P., Ling, W. (2013). Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: Findings from starting treatment with agonist replacement therapies (START). Journal of Studies on Alcohol and Drugs, 74, 605-613.
45. Rehm, J., Shield, K.D., Gmel, G., Rehm, M.X., & Frick, U. (2013). Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. European Neuropsychopharmacology, 23, 89-97.
46. Reifler, L.M., Droz, D., Bailey, J.E., Schnoll, S.H., Fant, R., Dart, R.C., Baertelson, B.B. (2012). Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Medicine, 13, 434-442.
47. Room, R., Babor, T., & Rehm, J. (2005). Alcohol and public health. The Lancet, 365, 519-530.
48. Schneider, J.P., Matthews, M., & Jamison, R.N. (2010). Abuse-deterrent and tamper-resistant opioid formulations: What is their role in addressing prescription opioid abuse? CNS Drugs, 24, 805-810.
49. Seal, K., Downing, M., Kral, A., Singleton-Banks, S., Hammond, J., Lorvick, J., Edlin, B.R. (2003). Attitudes about prescribing takehome naloxone to injection drug users for the management of heroin overdose: A survey of street-recruited injectors in the San Francisco bay area. Journal of Urban Health, 80, 291-301.
50. Sigmon, S.C., Dunn, K.E., Badger, G.J., Heil, S.H., & Higgins, S.T. (2009). Brief buprenorphine detoxification for the treatment of prescription opioid dependence: A pilot study. Addictive Behaviors, 34, 304-311.
51. Sigmon, S.C., Dunn, K.E., Saulsgiver, K., Patrick, M.E., Badger, G.J., Heil, S.H., Higgins, S.T. (2013). A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry, 70, 1347-1354.
52. Substance Abuse and Mental Health Services Administration (SAMHSA). (2012). Results from the 2011 national survey on drug use and health: Detailed tables. Retrieved November 25, 2012, from http://www.samhsa.gov/data/NSDUH/2011SummNatFindDetTables/NSDUH-DetTabsPDFWHTML2011/2k11DetailedTabs/Web/HTML/NSDUH-DetTabsLOTSect1pe2011.htm#TopOfPage.
53. The Health Officers Council of British Columbia. (2011). Public health perspectives for regulating psychoactive substances. Vancouver, BC: The Health Officers Council of British Columbia.
54. Trescot, A.M., Boswell, M.V., Atluri, S.L., Hansen, H.C., Deer, T.R., Abdi, S., Manchikanti, L. (2006). Opioid guidelines in the management of chronic non-cancer pain. Pain Physician, 9, 1-39.
55. Trescot, A.M., Glaser, S.E., Hansen, H., Benyamin, R., Patel, S., & Manchikanti, L. (2008). Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician, 11, S181-S200.
56. Turk, D.C., Swanson, K.S., & Gatchel, R.J. (2008). Predicting opioid misuse by chronic pain patients: A systematic review and literature synthesis. The Clinical Journal of Pain, 24, 497-508.
57. Veilleux, J.C., Colvin, P.J., Anderson, J., York, C., & Heinz, A.J. (2010). A review of opioid dependence treatment: Pharmacological and psychosocial interventions to treat opioid addiction. Clinical Psychology Review, 30, 155-166.
58. Vernick, J.S., & Teret, S.P. (2000). A public health approach to regulating firearms as consumer products. University of Pennsylvania Law Review, 148, 1193-1211.
59. Volkow, N.D., & McLellan, T.A. (2011). Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. The Journal of the American Medical Association, 305, 1346-1347.
60. Walley, A.Y., Xuan, Z., Hackman, H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ozonoff, A. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. BMJ (Clinical Research Ed.), 346, f174.
61. Wang, J., & Christo, P. (2009). The influence of prescription monitoring programs on chronic pain management. Pain Physician, 12, 507-515.
62. Webster, L.R., Bath, B., & Medve, R.A. (2009). Opioid formulations in development designed to curtail abuse: Who is the target? Expert Opinion on Investigational Drugs, 18, 255-263.
63. Webster, L.R., Cochella, S., Dasgupta, N., Fakata, K.L., Fine, P.G., Fishman, S.M., Wakeland, W. (2011). An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Medicine, 12, S26-S35.
64. Weiss, R.D., Potter, J.S., Fiellin, D.A., Byrne, M., Connery, H.S., Dickinson, W., Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Archives of General Psychiatry, 68, 1238-1246.
65. Wisniewski, A.M., Purdy, C.H., & Blondell, R.D. (2008). The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits. Journal of Addictive Diseases, 27, 1-11.
66. World Health Organization (WHO). (2010). Global strategy to reduce the harmful use of alcohol. Geneva, Switzerland: World Health Organisation.
67. Wunsch, M.J., Nakamoto, K., Behonick, G., & Massello, W. (2009). Opioid deaths in rural Virginia: A description of the high prevalence of accidental fatalities involving prescribed medications. The American Journal on Addictions, 18, 5-14.